ACR 2022 Tweet by TheDaoIndex
Tweet
Related Content
Treatment Landscape for Dermatomyositis Is Evolving
MedPage Today
Oct 12, 2026
After years of inactivity, therapeutic development for dermatomyositis has begun to move forward with several new therapies and therapeutic strategies."This is a very exciting time for the field because we're finally going to get some new treatments, and I think it will be helpful in our…
Podcast
DERM on RheumNow PODCAST (September 2026)
RheumNow
Sep 30, 2026
The Derm on RheumNow podcast is a review of recent citations and content curated for dermatologists – addressing Psoriasis, PsA, CLE, calcinosis, CTD skin disorders. dermatology drugs, biologics, and JAK inhibitors.
Features Dr. Jack Cush, Editor at RheumNow.com.
Show Notes:
FDA Grants Priority…
The EBR Journal Club Companion applies my adapted version of the JAMA approach to critical appraisal. Each review covers four domains: Does this apply to my patients? What is the risk of bias? How great are the benefits and harms? And what didn’t they show me? Feel free to use this in your own journal clubs! This edition: VALOR (brepocitinib in dermatomyositis).


